Lensar Inc - LNSR STOCK NEWS

Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), strengthening its cataract equipment portfolio. The acquisition includes LENSAR's ALLY Robotic Cataract Laser System, Streamline software, and legacy laser system.

The deal values LENSAR at $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 cumulative procedures between 2026-2027. The total potential consideration of $16.75 per share represents a 24% premium to LENSAR's 30-day VWAP and 47% to 90-day VWAP, potentially reaching $430 million.

The acquisition targets the growing cataract surgery market, with over 5 million procedures in the U.S. and 32 million globally. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.

LENSAR (NASDAQ: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members on March 3, 2025, allow the purchase of a total of 1,600 shares of common stock at $13.48 per share, matching the closing price on the grant date.

The options feature a vesting schedule where 25% vests after one year, followed by 36 monthly installments, contingent on continued employment. These 10-year term options were granted under LENSAR's 2024 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

LENSAR (NASDAQ: LNSR) reported strong Q4 and full-year 2024 results, with significant growth in ALLY Robotic Cataract Laser System placements and revenue. The company placed 31 ALLY systems in Q4, contributing to over 80 placements in 2024 - an 86% increase over 2023. Total installed systems reached approximately 385, up 26% from 2023.

Q4 2024 revenue increased 38% to $16.7 million, while full-year revenue grew 27% to $53.5 million. Recurring revenue exceeded $40 million for the year, up 23%. Worldwide procedure volumes grew 24% to nearly 170,000, with U.S. market share exceeding 20%. Despite positive operational metrics, the company reported a Q4 net loss of $18.7 million, primarily due to warrant liability changes from stock price appreciation.

For 2025, LENSAR expects revenue growth to accelerate beyond the 27% achieved in 2024, with Q1 2025 growth projected at 27% and further acceleration in subsequent quarters. The company anticipates achieving positive Adjusted EBITDA in 2025.

LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, has announced its schedule for releasing fourth quarter and full year 2024 financial results. The results will be released before market open on Thursday, February 27, 2025.

The company's management will host a conference call and webcast at 8:30 am ET on the same day to discuss financial results and recent corporate highlights. Participants must register in advance to join the telephone conference. A live webcast will be available in the Investor Relations section of LENSAR's website, with replay access available until March 20, 2025.

LENSAR (NASDAQ: LNSR) announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members, total 875 shares with an exercise price of $10.65 per share, matching the closing price on February 3, 2025.

The options will vest 25% on the one-year anniversary of the grant date, followed by thirty-six monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan and stock option agreements.

LENSAR (NASDAQ: LNSR) has announced the granting of stock options to three newly-hired non-executive employees. The independent board members approved options to purchase a total of 1,650 shares of common stock, effective January 2, 2025. The options were granted as employment inducements under Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.69 per share, matching the closing price on the grant date. The vesting schedule includes 25% of the total award after one year, followed by 36 monthly installments, contingent on continued employment. The options have a 10-year term and are governed by LENSAR's 2024 Employment Inducement Incentive Award Plan.

LENSAR (Nasdaq: LNSR) announced that its board of directors has granted stock options to four newly-hired non-executive employees. The grants total 2,475 shares of common stock at an exercise price of $7.70 per share, matching the closing price on December 8, 2024. The options will vest 25% after one year from December 2, 2024, with the remaining amount vesting in 36 monthly installments. Each option has a 10-year term and was granted under LENSAR's 2024 Employment Inducement Incentive Award Plan.

LENSAR (Nasdaq: LNSR), a global medical technology company specializing in robotic laser solutions for cataract treatment, announced its participation in the BTIG 4th Annual Ophthalmology Day. CEO Nick Curtis will engage in a fireside chat on December 2, 2024, at 2 p.m. ET. The company's management team will also conduct one-on-one meetings with institutional investors. The event is exclusively for current and prospective BTIG clients, who must contact their BTIG representative to access the live event.

LENSAR reported its Q3 2024 results, showing significant growth and operational updates. The company placed 24 ALLY Robotic Laser Cataract Systems™, including 11 sales in the EU and Southeast Asia, with a backlog of 24 systems pending installation. Revenue grew by 38% year-over-year to $13.5 million, driven by regulatory certifications in the EU and Taiwan. Recurring revenue grew 22% over the past twelve months. Worldwide procedure volumes increased by 29%, and the installed system base grew by 20%. The company's market share in the U.S. increased by 3.5% to 19.9%. Operating expenses rose to $7.5 million, but operating loss improved to $1.3 million. Net loss was $1.5 million, or ($0.13) per share, compared to net income of $2.6 million in Q3 2023. EBITDA was ($0.6) million, with adjusted EBITDA achieving break-even. Cash balance was $18.6 million as of September 30, 2024.